Immuno-Oncology | Specialty

Dr. Neal on Immunotherapy Combinations in Lung Cancer

October 27th 2016

Joel Neal, MD, PhD, assistant professor of Medicine (Oncology), Stanford University Medical Center, discusses what immunotherapy combinations oncologists are currently using in the treatment of patients with lung cancer.

First-Line Pembrolizumab Just the Beginning for Novel Approaches in Bladder Cancer

October 27th 2016

First-line pembrolizumab demonstrated significant antitumor activity in cisplatin-ineligible patients with metastatic urothelial cancer.

Novel Agents, Combinations Advance Second-Line RCC Care

October 27th 2016

The treatment paradigm of advanced renal cell carcinoma (RCC) has been rapidly changing. First, the FDA approved the combination of lenvatinib and everolimus in May 2016 as a treatment for patients with advanced RCC following prior antiangiogenic therapy.

Dr. Jonathan D. Schoenfeld on Radiation/Immunotherapy Combinations

October 27th 2016

Jonathan D. Schoenfeld, MD, MPhil, MPH, director, melanoma radiation oncology, physician, assistant professor of radiation oncology, Harvard Medical School, Dana-Farber Cancer Institute, discusses the potential benefit of using radiation and immunotherapy in combination.

Dr. Neeraj Agarwal on PROSTVAC and Other Immunotherapies in Prostate Cancer

October 27th 2016

Neeraj Agarwal, MD associate professor in the Division of Oncology, Department of Medicine, director of the Genitourinary Medical Oncology Program, Huntsman Cancer Institute at the University of Utah, discusses the pox viral vaccine rilimogene galvacirepvec/rilimogene glafolivec (PROSTVAC) and the future of immunotherapy in prostate cancer.

Dr. Zamarin on Immunotherapy as a Staple in the Future of Cancer Treatment

October 27th 2016

Dmitriy Zamarin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the ways in which immunotherapy is slated to play a major role in multiple cancer types.

Dr. Lukas on Immunotherapy in Glioblastoma

October 26th 2016

Rimas V. Lukas, MD, associate professor of Neurology, director, Medical Neuro-Oncology, University of Chicago Medicine, discusses some of the exciting advances recently seen with immunotherapy in the treatment of patients with glioblastoma

Dr. Mary Jo Fidler on the Role of Oligoclonal T Cell Expansion in NSCLC

October 26th 2016

Mary Jo Fidler, MD, associate professor, medical oncology, hematology, internal medicine, Rush University Medical Center, discusses how early and persistent oligoclonal T cell expansion correlates with durable response to anti-PD1 therapy in non-small cell lung cancer treatment (NSCLC).

Dr. Braghiroli on the Current and Future Treatment Landscape in CRC

October 26th 2016

Maria Ignez Braghiroli, MD, medical oncologist, Instituto do Câncer do Estado de São Paulo, discusses what the current treatment landscape looks like for patients with colorectal cancer, as well as what the future may hold.

Dr. Gerritsen on Shortcomings of Immunotherapy in Prostate Cancer

October 26th 2016

Winald Gerritsen, MD, PhD, professor and medical oncologist, Radboud Medical Center, discusses some of the recent shortcomings seen with immunotherapy agents in the treatment of patients with castration-resistant prostate cancer.

Dr. Marcus Bosenberg on Mouse and Other Models for Immunotherapy

October 26th 2016

Marcus Bosenberg, MD, PhD, associate professor of dermatology and pathology, Yale University, discusses mouse models for testing immunotherapies.

New Data Sustain Strong Benefit for Nivolumab in Hodgkin Lymphoma

October 26th 2016

Updated results from the CheckMate-205 trial showed that nivolumab had an objective response rate of 73% in a cohort of patients with classical Hodgkin lymphoma who received brentuximab vedotin before and/or after autologous hematopoietic stem cell transplantation.

Lead Researcher Discusses Promising Antibody-Drug Conjugate for Ovarian Cancer

October 25th 2016

Results from an expansion cohort of a preliminary clinical trial have shown encouraging activity for a novel antibody-drug conjugate in patients with heavily pretreated advanced ovarian cancer.

Dr. Wakelee on FDA Approval of Frontline Pembrolizumab in NSCLC

October 25th 2016

Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, regent, International Association for the Study of Lung Cancer (IASLC) discusses the FDA approval of pembrolizumab (Keytruda) in the frontline setting for patients with non–small cell lung cancer (NSCLC).

FDA Approves Pembrolizumab for Frontline PD-L1+ NSCLC

October 25th 2016

The FDA has approved pembrolizumab (Keytruda) for the frontline treatment of patients with metastatic non–small cell lung cancer whose tumors have ≥50% PD-L1 expression based on an FDA-approved test and who do not harbor EGFR or ALK aberrations.

Dr. Hossein Borghaei on Selecting Checkpoint Inhibitors in NSCLC

October 25th 2016

Hossein Borghaei, DO, associate professor at Fox Chase Cancer Center, discusses selecting between nivolumab (Opdivo) and pembrolizumab (Keytruda) in second-line non–small cell lung cancer (NSCLC).

Dr. Jeffery S. Weber on Sequencing of Nivolumab, Ipilimumab in Metastatic Melanoma

October 25th 2016

Jeffery S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discuses the key takeaways from the phase II CheckMate-064 trial, in which patients were randomized to receive either nivolumab followed by ipilimumab followed by nivolumab maintenance therapy, or ipilimumab followed by nivolumab and maintenance therapy with nivolumab.

Topalian Discusses the Evolution of PD-1/PD-L1 Inhibitors in Cancer Care

October 24th 2016

Suzanne L. Topalian, MD, discusses the development of PD-1/PD-L1 inhibitors, emerging biomarkers, and why a precision medicine approach is necessary to identify effective immunotherapy combination regimens.

Dr. Garon on Concerns for Immunotherapy Combinations in Lung Cancer

October 24th 2016

Edward B. Garon, MD, director, Thoracic Oncology, Jonsson Comprehensive Cancer Center, UCLA, discusses his concerns for potential immunotherapy combinations for the treatment of patients with lung cancer.

FDA Grants Nivolumab Priority Review for Urothelial Carcinoma

October 22nd 2016

The FDA has granted a priority review designation to nivolumab as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy.